GSK
aims for 1 billion doses with COVID vaccine booster plan
Send a link to a friend
[May 28, 2020]
(Reuters) - Britain's GlaxoSmithKline <GSK.L>
laid out plans on Thursday to produce 1 billion doses of vaccine
efficacy boosters, or adjuvants, next year as the race to develop and
produce a successful solution to the coronavirus crisis heats up.
|
The world's largest vaccine maker said it was in talks with
governments to back a manufacturing expansion that would help to
scale up production of future vaccines for COVID-19, the disease
caused by the novel coronavirus.
It gave no indication of the programme's costs, saying only that
production would take place at sites in Europe and North America and
that it would reinvest any profit into coronavirus research and
preparation for future pandemics.
GSK is working on its own COVID vaccine with French drugmaker Sanofi
<SASY.PA>, one of the many projects to counter the respiratory
illness that currently that has no treatment and has killed about
350,000 people.
Adjuvants, an area where GSK leads many of its peers, have been
shown to create a stronger and longer-lasting immunity against
infections and allow for lower dosing of the protein in a vaccine,
making way for higher-volume production.
"We believe that more than one vaccine will be needed to address
this global pandemic and we are working with partners around the
world to do so," said GSK Global Vaccines President Roger Connor.
[to top of second column] |
Experts have predicted that a successful vaccine will take more than a year to
develop and companies and governments are pouring money into dozens of
programmes as their best hope of allowing a durable escape from lockdowns and
get economies expanding again.
The United States last week secured almost a third of the first 1 billion doses
planned for AstraZeneca's <AZN.L> experimental COVID-19 vaccine by pledging up
to $1.2 billion.
On Thursday GSK said that making its adjuvant available to the world's poorest
countries will be a key part of its efforts.
(Reporting by Pushkala Aripaka and Aakash Jagadeesh Babu in Bengaluru and Ludwig
Burger in Frankfurt; Editing by Shounak Dasgupta and David Goodman)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|